Take a closer look at the complex spectrum between traditional SI and AU and discover new ingredients for life products that can increase customer satisfaction, attract the right risks, and maintain low mortality.
What last year’s explosion means for the future of policy
Marijuana use in the United States has exploded over the past decades, with legal sales of various products reaching an estimated $30 billion in 2022.
In a new research paper, RGA experts Guizhou Hu and Taylor Pickett examine the impact of LabPiQture (LP), a commercial data product of ExamOne, on the mortality slippage of standard and better risk classes in non-fluid underwriting.
Fifty-eight percent of life insurers are either using or have an interest in using artificial intelligence in their businesses, an NAIC working group found.
Insurers must be anticipatory, and evolve in the rapidly changing scientific, legal, and regulatory genomics landscape.
Executives, underwriters, sales leaders, and actuaries are eager to take their underwriting systems to the next level but may face challenges as they explore automated underwriting options. Find out the facts about how a custom AU solution is implemented and scaled with minimal disruption to your organization and team.
Munich Re’s medical experts respond to challenging underwriting scenarios
Fibromyalgia is a disease categorized by widespread musculoskeletal pain, fatigue and poor sleep of at least three months duration that is not characterized by any other systemic or rheumatic disorder.
In a new white paper, RGA experts Mark Ma, Guizhou Hu, and Taylor Pickett present the results of their actuarial validation of Milliman Irix® – Risk Score 3.0 with Credit, a commercial risk-scoring product that combines prescription drug, medical billing, and credit data to generate four different scores for mortality risk segmentation.